Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 7:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1825–1848 of 16,130 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Skin Disorder Clear all

Conditions: Obesity and Overweight, Breast Cancer Survivorship
Interventions: Broccoli microgreen (BMG); Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Kohlmeier-Degos Disease, Malignant Atrophic Papulosis, Degos Disease, Papulosis, Malignant Atrophic
Interventions: Baricitinib; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Tripelennamine, Diphenhydramine, Vehicle Control Cream Base; Drug
Lead sponsor: Palm Beach Atlantic University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: West Palm Beach, Florida

Conditions: Atopic Dermatitis, Healthy, Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus
Interventions: Skin Taping, Blood Sampling, Skin Biopsy; Procedure
Lead sponsor: Biogen; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Kawasaki Disease
Interventions: Defibrotide; Drug
Lead sponsor: New York Medical College; Other
Eligibility: 0 Years to 11 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: New York, New York • Valhalla, New York

Conditions: Breast Cancer
Interventions: Bevacizumab, Cyclophosphamide, Docetaxel; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2015
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Rheumatoid Arthritis
Interventions: Adalimumab, Placebo; Biological · Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 619 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 76
States / cities: Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 64 more

Conditions: Arthritis, Rheumatoid
Interventions: GSK3196165 (Otilimab), Tofacitinib, Placebo; Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 1,764 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 64
States / cities: Flagstaff, Arizona • Glendale, Arizona • Mesa, Arizona + 58 more

Conditions: Rheumatoid Arthritis
Interventions: Veltuzumab; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 8
States / cities: La Mesa, California • Los Angeles, California • Upland, California + 5 more

Conditions: Melanoma
Interventions: Pembrolizumab/Vibostolimab, Pembrolizumab; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 12 Years and older
Enrollment: 1,594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 30
States / cities: La Jolla, California • Los Angeles, California • San Francisco, California + 22 more

Conditions: Abscess, Wound Infection, Surgical Site Infection, Cellulitis
Interventions: IV Dalbavancin, Vancomycin/Linezolid; Drug
Lead sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 739 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 30
States / cities: Montgomery, Alabama • Anaheim, California • Buena Park, California + 26 more

Conditions: Breast Cancer
Interventions: CT scans, DEXA scan; Diagnostic Test
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Psoriasis
Interventions: Enstilar; Drug
Lead sponsor: Psoriasis Treatment Center of Central New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: East Windsor, New Jersey

Conditions: Melanoma, Malignant Melanoma, Melanoma, Experimental
Interventions: DMF5 Melanoma Reactive TIL, Cyclophosphamide, Fludarabine, Aldesleukin; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Granulomatosis With Polyangiitis, Microscopic Polyangiitis
Interventions: Glucocorticoids, Rituximab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Metastatic Breast Cancer, Breast Tumor, Advanced Gynecologic Cancer
Interventions: Genetic profiling; Genetic
Lead sponsor: Avera McKennan Hospital & University Health Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease
Interventions: APL-2; Drug
Lead sponsor: Apellis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 17
States / cities: Stanford, California • Aurora, Colorado • Denver, Colorado + 14 more

Conditions: Acne Vulgaris
Interventions: SB204; Drug
Lead sponsor: Novan, Inc.; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Broomall, Pennsylvania

Conditions: Herpes Simplex Infection
Interventions: HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine, Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 30 Years · Female only
Enrollment: 8,323 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 67
States / cities: Birmingham, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more

Conditions: Ovarian Cancer, TNBC, SCLC, Other Solid Tumours
Interventions: AZD 1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 13
States / cities: Fayetteville, Arkansas • San Francisco, California • West Hollywood, California + 10 more

Conditions: Advanced/Metastatic HER2-negative Breast Cancer
Interventions: No drug; Other
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 1,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Rheumatoid Arthritis
Interventions: Placebo, PF-06651600; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Northridge, California • St Louis, Missouri • Duncansville, Pennsylvania + 1 more

Conditions: Sarcoma, Kaposi, HIV Infections, Lymphoproliferative Disorders
Interventions: A-007; Drug
Lead sponsor: DEKK-TEC, Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Breast Cancer
Interventions: ritonavir, therapeutic conventional surgery; Drug · Procedure
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Philadelphia, Pennsylvania

Search by objective public record fields.

Metabotyping of Broccoli Microgreen in Obese Breast Cancer Survivors

Baricitinib in the Treatment of Kohlmeier-Degos Disease in Patients With Neurological Involvement

Topical Tripelennamine 1% Cream Versus Diphenhydramine 1% Cream for the Relief of Histamine-Induced Itching: A Proof Concept Study in Healthy Adults.

Pilot Tape Harvesting Study

Defibrotide in Children With High Risk Kawasaki Disease

Primary Systemic Therapy in Operable/Locally Advanced Breast Cancer

Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.

Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs)

VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis

A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections

CDK and Body Composition Study

Taltz in Combination With Enstilar for Psoriasis

Chemotherapy Followed by Infusion of DMF5 Cells to Treat Metastatic Melanoma

Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated Vasculitis

Genomic and Proteomic Profiling Targets Influenced Treatment in Metastatic Breast Cancer

Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies

A Phase 1 Study Assessing Local Cutaneous Effects of SB204

HerpeVac Trial for Young Women

Safety, Tolerance, PK, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Real-World Outcomes of Patients With Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i

Study To Assess The Efficacy And Safety Of Pf-06651600 In Subjects With Rheumatoid Arthritis With An Inadequate Response To Methotrexate

Topical Use of 4,4'-Dihydroxybenzophenone-2,4-Dinitrophenylhydrazone (A-007) in the Treatment of Advanced Malignancies Including Kaposi's Sarcoma and Lymphoproliferative Disorders

Ritonavir and Its Effects on Biomarkers in Women Undergoing Surgery for Newly Diagnosed Breast Cancer